Novo Nordisk receives positive opinion from the European regulatory authorities for Refixia® (nonacog beta pegol, N9-GP) for the treatment of haemophilia B
(WorldNews Denmark)

Novo Nordisk receives positive opinion from the European regulatory authorities for Refixia®(nonacog beta pegol, N9-GP) for the treatment of haemophilia B Bagsværd, Denmark, 24 March 2017 - Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP), under the European Medicines Agency (EMA), adopted a positive opinion for the use of Refixia®(nonacog beta pegol, N9-GP), recommending marketing authorisation for the treatment of adolescents and adults with haemophilia B. The CHMP recommends Refixia®, the brand name for nonacog beta pegol, N9-GP, to be indicated for...